X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
onCARlytics (CF33-CD19) is a novel CD19 oncolytic virotherapy drug candidate, which is being evaluated for the treatment of patients with advanced solid tumors.
Lead Product(s): CF33-CD19,Blinatumomab
Therapeutic Area: Oncology Product Name: onCARlytics
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
BLINCYTO (blinatumomab) is a BiTE® (bispecific T-cell engager) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE molecules fight cancer by helping the body's immune system detect and approval for ACUTE LYMPHOBLASTIC LEUKEMIA.
Lead Product(s): Blinatumomab
Therapeutic Area: Oncology Product Name: Blincyto
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
onCARlytics (CF33-CD19, HOV4) is a live, attenuated oncolytic orthopox (vaccinia) virus engineered to encode a truncated human CD19 transgene, resulting in expression of de novo CD19 at the tumour cell surface before virus-mediated tumour cell lysis.
Lead Product(s): CF33-CD19,Blinatumomab
Therapeutic Area: Oncology Product Name: onCARlytics
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
BLINCYTO is a BiTE® (bispecific T-cell engager) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells.
Lead Product(s): Blinatumomab,Cyclophosphamide,Cytarabine
Therapeutic Area: Oncology Product Name: Blincyto
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
BLINCYTO demonstrated significantly prolonged event-free survival (events were defined by relapse, death, second malignancy, or failure to achieve complete remission) compared with chemotherapy. Phase 3 Results published in The journal of The American Medical Association.
Lead Product(s): Blinatumomab
Therapeutic Area: Oncology Product Name: Blincyto
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
